A team of researchers in Germany has developed a new assay to help determine which non-small cell lung cancers are likely to respond to certain targeted therapies.
As a screen for gene rearrangements, the assay uses quantitative reverse transcription-PCR to show altered ratios of 3' to 5' ends of the aplastic lymphoma tyrosine kinase, or ALK gene, rather than specific mutations. It is also optimized to work on formalin-fixed paraffin-embedded tissue samples.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
